Actively Recruiting
Study of Lacosamide Added to Treatment for Moderate to Severe Depressive Episodes in Bipolar Disorder Types I and II A Randomized, Double-Blind, Placebo-Controlled Trial Over 12 Weeks
Led by University of Sao Paulo · Updated on 2026-02-20
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of lacosamide as an add-on treatment for moderate to severe major depressive episodes in adults with bipolar disorder types I and II who have not responded to at least two adequate treatments during their current episode. This randomized, double-blind, placebo-controlled pilot study aims to compare the reduction in depression symptoms between lacosamide and placebo groups over 12 weeks. Participants will receive either lacosamide or placebo tablets. Lacosamide will be given at 50 mg twice daily for the first two weeks, followed by 100 mg twice daily for the remainder of the 12-week treatment period. The study includes two groups an active treatment group receiving lacosamide and a placebo group receiving inactive tablets that look similar to the active drug. During the study, participants will be assessed for changes in their depression severity using the Hamilton Depression Rating Scale HAMD-17 from the beginning to the end of the 12 weeks. Researchers will also monitor side effects and adverse events to compare safety between groups. The total study duration for each participant is 12 weeks, during which their response to treatment and tolerability will be closely evaluated.
CONDITIONS
Brief Title
Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.
Research Team
R
Ricardo Alberto Moreno, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here